Biomx
Yahoo Finance • 2 months ago
BiomX Inc (NYSEARCA:PHGE) Surges 142% After Stunning Q2 2025 Earnings Beat and Promising BX211 Phase 2 Results
BiomX Inc (NYSEARCA:PHGE [https://www.chartmill.com/stock/quote/PHGE/profile]) reported its second-quarter 2025 financial results, delivering a significant earnings surprise that has fueled a sharp upward movement in its stock price. The c... Full story
Yahoo Finance • 2 months ago
Most active stocks in Wednesday's session
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the most active stocks in today's session. [mostactive] TOP MOST ACTIVE STOCKS TICKER CHANGE COMMENT SGBX [https://www.chartmill.com/st... Full story
Yahoo Finance • 2 months ago
BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025
NESS ZIONA, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria,... Full story
Yahoo Finance • 3 months ago
BiomX begins phase 2b trial for phage therapy targeting CF infections
NESS ZIONA, Israel - BiomX Inc. (NYSE American:PHGE), a clinical-stage biotech company with a market capitalization of $10.9 million, has initiated patient dosing in its Phase 2b clinical trial evaluating BX004, a phage therapy targeting a... Full story
Yahoo Finance • 2 years ago
BiomX to Present Data from Ongoing Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis at the 37th Annual North American Cystic Fibrosis Conference
CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific... Full story
Yahoo Finance • 2 years ago
BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors
CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific p... Full story
Yahoo Finance • 3 years ago
BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023
BiomX CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target spe... Full story
Yahoo Finance • 3 years ago
BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients
Live Webinar Event to be Held on Thursday, May 12th, 11:00 AM EDT BRANFORD, Conn. & NESS ZIONA, Israel, May 06, 2022--(BUSINESS WIRE)--BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage microbiome company advanc... Full story
